Alfred Altomari - 26 Aug 2022 Form 4 Insider Report for AGILE THERAPEUTICS INC

Role: Chief Executive Officer, Director
Signature: /s/ Geoffrey P. Gilmore, Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 26 Aug 2022
Net transactions value: +$22,500
Form type: 4
Filing time: 29 Aug 2022, 08:30:25 UTC
Previous filing: 13 May 2022
Next filing: 14 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGRX	Common Stock	Purchase	$22,500	+50,000	+349%	$0.4500^*	64,343	26 Aug 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4467 to $0.4498, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4467 to $0.4498, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.